Selecting the Right Patients for Anti-VEGF Biosimilar TherapyByThis program is initiated, funded, and developed by Biogen.April 18th 2024
Impact of Biosimilars on the Healthcare SystemByThis program is initiated, funded, and developed by Biogen.April 18th 2024
Key Clinical Findings on the Efficacy, Safety Profile and Immunogenicity of Biosimilar SB11ByThis program is initiated, funded, and developed by Biogen.April 18th 2024
Review of the Phase III Clinical Trial for Biosimilar SB11ByThis program is initiated, funded, and developed by Biogen.April 18th 2024
Biosimilar Approval Process by Regulatory BodiesByThis program is initiated, funded, and developed by Biogen.April 18th 2024
Need for Awareness About BiosimilarsByThis program is initiated, funded, and developed by Biogen.April 18th 2024
